Teva Pharmaceutical Industries Ltd.
Suletud
SektorTervishoid
36.35 -0.66
Ülevaade
Aktsiahinna muutus
24h
Min
35.99
Max
36.9
Sissetulek | -944M -575M |
|---|---|
Müük | 161M 4.1B |
P/E Sektori keskmine | 61.102 56.659 |
Aktsiakasum | 0.64 |
Kasumimarginaal | -13.882 |
Töötajad | 31,173 |
EBITDA | -896M -19M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +19.77% upside |
Turukapital | 5.8B 42B |
|---|---|
Eelmine avamishind | 37.01 |
Eelmine sulgemishind | 36.35 |
Teva Pharmaceutical Industries Ltd. Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Teva Pharmaceutical Industries Ltd. Prognoos
Hinnasiht
By TipRanks
19.77% tõus
12 kuu keskmine prognoos
Keskmine 43.86 USD 19.77%
Kõrge 50 USD
Madal 40 USD
Põhineb 9 Wall Streeti analüütiku instrumendi Teva Pharmaceutical Industries Ltd. 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.